Objective Safety net health care centers in the US serve vulnerable and underinsured females. The primary aim of this work was to determine if HPV4 dosing compliance differs between females who receive doses at rural vs. urban core safety net health care locations. Methods Females exclusively receiving health care in the Truman Medical Center (TMC) safety net system at the urban core and rural locations were identified by their HPV4 vaccine records. Dates and number of HPV4 doses as well as age, gravidity, parity and race/ethnicity were recorded from the electronic medical record (EMR). Appropriate HPV4 dosing intervals were referenced from the literature. Results 1259 females, 10–26 years of age, received HPV4 vaccination at either the rural (23%) or urban core location (77%). At the rural location, 23% received three doses on time, equal to the 24% at the urban core. Females seen in the urban core were more likely to receive on-time doublet dosing than on-time triplet dosing (82% vs. 67%, p<0.001). Mistimed doses occurred equally often among females receiving only two doses, as well as those receiving three doses. Conclusions Compliance with on-time HPV4 triplet dose completion was low at rural and urban core safety net health clinics, but did not differ by location.
References
[1]
US Department of Health and Human Services (2011) 2010 National Healthcare Disparities Report. AHRQ Publication no. 11-0005. Available at www.ahrq.gov/qual/qrdr10.htm. Accessed on July 31, 2013.
[2]
Wu X, Watson M, Wilson R, Saraiya M, Cleveland JL, et al. (2012) Human Papillomavirus–Associated Cancers — United States, 2004–2008. MMWR 61: 258–261.
[3]
Spoont M, Greer N, Su J, Fitzgerald P, Rutks I, et al. (2011) Rural vs. Urban Ambulatory Health Care: A Systematic Review. VA-ESP Project #09-009.
[4]
Krieger JL, Katz ML, Kam JA, Roberto A (2012) Appalachian and non-Appalachian pediatricians' encouragement of the human papillomavirus vaccine: implications for health disparities. Womens Health Issues. 22: e19–26. doi: 10.1016/j.whi.2011.07.005
[5]
Reiter PL, Katz ML, Paskett ED (2012) HPV vaccination among adolescent females from Appalachia: implications for cervical cancer disparities. Cancer Epidemiol Biomarkers Prev. 21: 2220–30 doi:10.1158/1055-9965.
[6]
Mills LA, Head KJ, Vanderpool RC (2013) HPV vaccination among young adult women: a perspective from Appalachian Kentucky. Prev Chronic Dis. 10: E17 doi:10.5888/pcd10.120183.
[7]
Moss JL, Gilkey MB, Reiter PL, Brewer NT (2012) Trends in HPV vaccine initiation among adolescent females in North Carolina, 2008–2010. Cancer Epidemiol Biomarkers Prev 21: 1913–22. doi: 10.1158/1055-9965.epi-12-0509
[8]
Yabroff KR, Lawrence WF, King JC, Mangan P, Washington KS, et al. (2005) Geographic disparities in cervical cancer mortality: what are the roles of risk factor prevalence, screening, and use of recommended treatment? J Rural Health. 21: 149–57. doi: 10.1111/j.1748-0361.2005.tb00075.x
[9]
Casey MM, Thiede Call K, Klingner JM (2001) Are rural residents less likely to obtain recommended preventive healthcare services? Am J Prev Med. 21: 182–8. doi: 10.1016/s0749-3797(01)00349-x
[10]
Regan J, Schempf AH, Yoon J, Politzer RM (2003) The role of federally funded health centers in serving the rural population. J Rural Health. 19: 115–24. doi: 10.1111/j.1748-0361.2003.tb00552.x
[11]
Frick KD, Regan J (2001) Whether and where community health center users obtain screening services. J Health Care Poor Underserved. 12: 429–45. doi: 10.1353/hpu.2010.0787
[12]
Adams SA, Bellinger JD, Gallagher A, Probst JC (2013) Report 1: Diffusion of Preventive Innovation: Racial and Rural Differences in Cervical Cancer Prevention and Control Practices. South Carolina Rural Health Research Center. Available at http://rhr.sph.sc.edu. Accessed 2013 July 31.
[13]
Verdenius I, Harper DM, Harris GD, Griffith RS, Wall J, et al. (2013) Predictors of Three Dose On-Time Compliance with HPV4 Vaccination in a Disadvantaged, Underserved, Safety Net Population in the US Midwest. PLoS ONE 8(8): e71295 doi:10.1371/journal.pone.0071295.
[14]
Markowitz LE, Dunne EF, Saraiya M, Lawson WH, Chesson H, et al. (2007) Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56: 1–24.
[15]
Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, et al. (2013) Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women: A Randomized Clinical Trial. JAMA 309: 1793–1802 doi:10.1001/jama.2013.1625.
[16]
Smolen KK, Gelinas L, Franzen L, Dobson S, Dawar M, et al. (2012) Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 30: 3572–9. doi: 10.1016/j.vaccine.2012.03.051
[17]
Neuzil KM, Canh do G, Thiem VD, Janmohamed A, Huong VM, et al. (2011) Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA 305: 1424–31. doi: 10.1001/jama.2011.407
[18]
Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, et al. (2011) Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 103: 1444–51. doi: 10.1093/jnci/djr319
[19]
Harper DM, Vierthaler SL (2011) Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females. ISRN Obstet Gynecol. 2011: 457204. doi: 10.5402/2011/457204
[20]
Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, et al. (2012) Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13 (1) 100–10. doi: 10.1016/s1470-2045(11)70287-x
[21]
Szarewski AM, Skinner SR, Garland SM, Romanowski B, Schwarz TF, et al. (2013) Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low risk HPV Types (PATRICIA randomised trial): an unexpected observation. JID 208: 1391–6 doi:10.1093/infdis/jit360.
[22]
IBM Corp (2011) IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.
[23]
IBM Corp (2012) Cochran-Armitage test for trend for 2xl tables. [updated Jan 4 2012] Available at: http://www-01.ibm.com/support/docview.ws？s?uid=swg21480127. accessed 2013 July 31.
[24]
StatSoft, Inc (2010) STATISTICA (data analysis software system), version 9.1 Available from: www.statsoft.com. Accessed 2013 July 31.
[25]
Williams W, Lu PJ, Singleton JA, Bridges CB, Wortley PM, et al. (2012) Centers for Disease Control and Prevention. Adult Vaccination coverage – United States, 2010. MMWR 61: 66–72.
[26]
Dorell C, Stokely S, Yankey D, Jeyarajah J, MacNeil J, et al. (2011) Centers for Disease Control and Prevention. National and State Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2011. MMWR 60: 671–677.
[27]
Tiro JA, Pruitt SL, Bruce CM, Persaud D, Lau M, et al. (2012) Multilevel correlates for human papillomavirus vaccination of adolescent girls attending safety net clinics. Vaccine. 30: 2368–75. doi: 10.1016/j.vaccine.2011.11.031
[28]
Perkins RB, Brogly SB, Adams WG, Freund KM (2012) Correlates of human papillomavirus vaccination rates in low-income, minority adolescents: a multicenter study. J Womens Health (Larchmt). 21 (8) 813–20. doi: 10.1089/jwh.2011.3364
[29]
Cook RL, Zhang J, Mullins J, Kauf T, Brumback B, et al.. (2010) Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid. J Adolesc Health 47 (6): 596–9.
[30]
Grant D, Hurley J, Williams H, McLaulin S, Rollins L, et al. (2012) Department of Health and Human Services. Office of Inspector General. Vaccines for Children Program: Vulnerabilities in vaccine management. OEI-04-10-00430 June 2012. https://oig.hhs.gov/oei/reports/oei-04-1？0-00430.asp. Accessed 2013 August 1.
[31]
Setia S, Mainzer H, Washington ML, Coil G, Snyder R, et al. (2002) Frequency and causes of vaccine wastage. Vaccine. 20: 1148–56. doi: 10.1016/s0264-410x(01)00433-9
[32]
Raymond P (2011) Rhode Island Department of Health. HPV4 Immunization Program Update. November 30, 2011 Available at http://www.health.ri.gov/publications/po？licies/HPVVaccinePolicyUpdate.pdf. Accessed 2013 August 1.
[33]
Scarinci IC, Garcia FA, Kobetz E, Partridge EE, Brandt HM, et al. (2010) Cervical cancer prevention: new tools and old barriers. Cancer. 116: 2531–42. doi: 10.1002/cncr.25065
[34]
Schootman M, Fuortes LJ (1999) Breast and cervical carcinoma: the correlation of activity limitations and rurality with screening, disease incidence, and mortality. Cancer. 86: 1087–94. doi: 10.1002/(sici)1097-0142(19990915)86:6<1087::aid-cncr27>3.0.co;2-i
[35]
Hopenhayn C, King JB, Christian A, Huang B, Christian WJ (2008) Variability of cervical cancer rates across 5 Appalachian states, 1998–2003. Cancer. 113: 2974–80. doi: 10.1002/cncr.23749
[36]
Battaglia TA, Santana MC, Bak S, Gokhale M, Lash TL, et al. (2010) Predictors of timely follow-up after abnormal cancer screening among women seeking care at urban community health centers. Cancer. 116: 913–21 doi:10.1002/cncr.24851.
[37]
Probst JC, Moore CG, Baxley EG (2005) Update: health insurance and utilization of care among rural adolescents. J Rural Health. 21: 279–87. doi: 10.1111/j.1748-0361.2005.tb00096.x
[38]
Martin A, Probst JC, Moore CG, Patterson D, Elder K (2005) Report 17: Trends in Uninsurance among Rural minority children. South Carolina Rural Health Research Center. Available at http://rhr.sph.sc.edu. Accessed 2013 July 31.
[39]
Heitmann ER, Harper DM (2012) Prophylactic HPV vaccines and prevention of cervical intraepithelial neoplasia. urrent Obstetrics and Gynecology Reports. 1: , 95–105.
[40]
Demarteau N, Breuer T, Standaert B (2012) Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program. Pharmacoeconomics. 30: 337–53. doi: 10.2165/11591560-000000000-00000
